News for Verve Therapeutics, Inc. (VERV)

The big healthcare stocks are not keeping up with wider stock market. When the S&P 500 and the Nasdaq 100 recently popped to new highs, this sector vastly underperformed.

Follow The Leaders - Here Are The 50 Strongest Stocks Of 2025. Here are the strongest stocks of 2025.

PR NewswireNEW YORK, June 27, 2025 NEW YORK, June 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up […]

Eli Lilly (LLY) plans a strategic acquisition of Verve Therapeutics (VERV) for up to $1.3 billion, with a significant upfront cash payment. Analysts pro

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Shares of Verve Therapeutics (VERV) saw a significant movement recently, with its price declining by 0.49% to $11.065. This comes in the wake of a noteworthy ac

Lilly is acquiring an exciting new program with the agreement to buy Verve Therapeutics. Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve.

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the ”œM&A Class Action Firm”), has recov

PR NewswireNEW YORK, June 19, 2025 NEW YORK, June 19, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

International Business News: Wall Street remained steady as investors awaited the Federal Reserve's policy decision, while global markets reacted to fluctuating oil prices and tra

Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash, an aggregate of approximately $1B, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share. Published first on Th

On June 18, 2025, HC Wainwright & Co. analyst Mitchell Kapoor announced a downgrade for Verve Therapeutics (VERV), changing the stock's rating from

On June 18, 2025, Verve Therapeutics (VERV) experienced a notable change in its analyst ratings and price target, as reported by LifeSci Capital. Analyst Cory J

On June 18, 2025, Jefferies analyst Roger Song downgraded Verve Therapeutics (VERV) from a "Buy" rating to a "Hold" rating. This change reflects a shift in Jeff

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Asian shares are mixed and oil prices have advanced after the escalation of conflict in the Middle East hit Wall Street

U.S. stocks declined on Tuesday amid escalating tensions in the Middle East, as the Israel-Iran conflict intensified and the U.S. military increased its presence in the region. Investors also reacted to disappointing U.S. retail sales and factory production data, while awaiting the Federal Reserve's monetary policy decision.